# Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine

> **NCT00962780** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 303 (actual)

## Conditions studied

- HIV Infections
- Pneumococcal Infections

## Interventions

- **BIOLOGICAL:** 13-valent Pneumococcal Conjugate Vaccine (13vPnC)
- **BIOLOGICAL:** 23-valent Pneumococcal Polysaccharide Vaccine (23vPS)
- **PROCEDURE:** Blood draw
- **PROCEDURE:** Blood draw

## Key facts

- **NCT ID:** NCT00962780
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 303 (ACTUAL)
- **Last updated:** 2014-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00962780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00962780, "Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00962780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*